Oct 2, 2018 [Tue]

SY01: MDO 50 Years Anniversary #1
Frank J. Gonzalez (National Cancer Institute, USA)
Role of PPARα in physiology and hepatocarcijnogenesis

Masahiko Negishi (National Institutes of Health, USA)
Phenobarbital drives CAR into the nuclear receptor world

M. Almira Correia (University of California, San Francisco, USA)
From microsomal cytochromes and drug oxidations to P450 ERAD: Fascinating travels in and out of the ER

Yuichi Sugiyama (RIKEN, Japan)
PBPK analyses of interplay between transporters (uptake, efflux) and enzymes
Yuichi Sugiyama (RIKEN, Japan)
SY02: Needs meet Seeds -Unlimited potential of Liver Microphysiological System-
Masato Ohbuchi (Astellas Pharma Inc., Japan)
Needs for Liver Microphysiological System in Drug Discovery Research -Lessons from Bioprinted Human Liver Tissue Model-

Takafumi Komori (Eisai Co. Ltd., Japan)
Industrial perspective on MPS technology as advanced in vitro ADME model in pharmaceutical development

Hiroshi Kimura (Tokai University, Japan)
Organ(s)-on-chips mimicking physiological parameters

Kenichiro Kamei (Kyoto University, Japan)
Body on a Chip to recapitulate physiological conditions in vitro

Yoshimasa Saito (Keio University, Japan)
Establishment of preclinical models for refractory cancers by organoid culture and its application for drug discovery

Tamihide Matsunaga (Nagoya City University, Japan)
Development of biomimetic small intestine- and liver-on-a-chip to assess pharmacokinetics
SY03: Metabolomics in Diseases and Translational Research
Wei Jia (University of Hawaii Cancer Center, USA)
Bile acid-microbiota crosstalk in drug metabolism and gastrointestinal carcinogenesis

Andrew D Patterson (Pennsylvania State University, USA)
Multi-platform metabolic profiling to understand microbiome toxicity

Mitsutoshi Setou (Hamamatsu University School of Medicine, Japan)
Mass spectrometry imaging for metabolomics in diseases and translational research
SY04: New Perspectives on Intestinal Drug Absorption and Metabolism
Yoshiyuki Shirasaka (Tokyo University of Pharmacy and Life Sciences, Japan)
Osmolality of orally administered solutions influences luminal water volume and drug absorption in intestine

Akihiro Hisaka (Chiba University, Japan)
Discrimination of metabolism and transport contributions in intestinal clearance by mechanistic static model

K. Sandy Pang (University of Toronto, Canada)
Physiologically based pharmacokinetic modeling of intestinal metabolism
SY05: Drug Metabolism in Special Populations: Ethnic, Renal Failure, Obesity and Pediatric Patients
Shin-ichi Inoue (Daiichi Sankyo Co. Ltd., Japan)
Inter-ethnic diffrences in drug metabolism

Ken-ichi Fujita (Showa University, Japan)
Severe renal failure and drug disposition

Yoshimichi Sai (Kanazawa University, Japan)
Effects of obesity on inter-individual variation of drug metabolism

Ikuko Yano (Kobe University, Japan)
Drug mtabolism in pediatric population
SY06: Structure Based Approaches to Enhance Drug Efficacy and Safety
Emily Scott (University of Michigan, USA)
Structure/Function of steroidogenic cytochrome P450 enzymes

Irina Pikuleva (Case Western Reserve University, USA)
Repurposing of efavirenz, an anti-HIV medication, for treatment of Alzheimer's disease

Andrew Munro (University of Manchester, UK)
Targeting CYP enzymes in the human pathogen Mycobacterium tuberculosis

Shingo Nagano (Tottori University, Japan)
Structural biology of plant steroid hormone brassinosteroid biosynthesis
SY07: Ah Receptor: Relevance to Xenobiotic Metabolism and Physiological Processes
Yongna Xing (University of Wisconsin-Madison, USA)
Structural allostery for endogenous and aberrant AHR signaling

Bhagavatula Moorthy (Baylor College of Medicine, USA)
Mechanistic role of CYP1 family in oxygen-mediated lung toxicity: Novel function of the endogenous Ah receptor ligand FICZ in CYP1 induction and hyperoxic injury

Masutaka Furue (Kyushu University, Japan)
Ah receptor: relevance to xenobiotic metabolism and physiological processes, AHR and skin
SY08: Development and Appropriate Use of Drugs for New-born Infants to Children
Hidefumi Nakamura (National Center for Child Health and Development, Japan)
Current status of pediatric drug development in the US, EU and Japan

Jumpei Saito (National Center for Child Health and Development, Japan)
The Current state of and issues regarding pediatric formulations in Japan: how can we facilitate the age-appropriate drug development?

Tomoki Takechi (Maruho Co. Ltd., Japan)
Clinical trials and researches in drug development companies -(1) Efficacy, Safety, and Pharmacokinetics of Oral Propranolol (Hemangiol® Syrup for Pediatric) in Infants with Infantile Hemangioma-

Takahiro Tanigawa (Bayer Yakuhin Ltd., Japan)
Clinical trials and researches in drug development companies -(2) Clinical Trials of Direct Oral Anticoagulants in the Pediatric Population-

Kimio Terao (Chugai Pharmaceutical Co. Ltd., Japan)
Clinical trials and researches in drug development companies -(3) Lessons and learnt from clinical trials conducted by pharma industries-
SY09: Non-CYP Phase I
Matthew A. Cerny (Pfizer Inc., USA)
Is non-cytochrome P450 metabolism becoming more prevalent? A review of FDA–approved drugs: 2005–Present

Enrico Garattini (Mario Negri, Italy)
Aldehyde oxidases an emerging group of drug metabolizing enzymes: evolutionary, structural and functional insights.

Tatsuki Fukami (Kanazawa University, Japan)
Novel characterization of main drug-metabolizing hydrolases: AADAC, CES1, and CES2

Yanqiao Zhang (Northeast Ohio Medical University, USA)
Role of carboxylesterases 1 and 2 in lipid metabolism

Oct 3, 2018 [Wed]

SY10: Frontier Science of Transporter Research Based on Innovative Ideas
Yoshinori Fujiyoshi (Nagoya University, Japan)
Structural analysis of membrane protein with the use of cryogenic electron microscope

Satoru Koyanagi (Kyushu University, Japan)
Circadian rhythm of transporter function and its impact on pharmacological/toxicological effects

Noritaka Nakamichi (Takasaki University of Health and Welfare, Japan)
Functional regulation of neural stem cells by transporters

Atsushi Yonezawa (Kyoto University, Japan)
Functional analysis of a novel riboflavin transporter, RFVT, and its impact on genetic disease
SY11: Importance of ncRNAs in Drug Disposition and Response
Michael H Court (Washington State University, USA)
MicroRNAs as mediators and markers of interindividual variability in human drug glucuronidation

Aiming Yu (University of California, Davis, USA)
MicroRNAs modulate transporter expression and chemosensitivity

Xiaobo Zhong (University of Connecticut, USA)
Getting bigger: Long noncoding RNAs in liver metabolism

Baitang Ning (Food and Drug Administration, USA)
Functional Characterization of Non-Coding RNAs in the Regulation of Drug Metabolizing Enzymes and Transporters
SY12: Emerging Trends in Drug Development of Peptide- and Antibody-based Therapeutics
Keiichi Masuya (PeptiDream Inc., Japan)
ADME of constrained peptides

Shiroh Futaki (Kyoto University, Japan)
Peptide-mediated delivery of antibodies and bioactive proteins into cells

Yoko Nagai (Daiichi Sankyo Co. Ltd., Japan)
Preclinical pharmacokinetic profile of DS-8201a (trastuzumab deruxtecan), a novel anti-HER2 ADC

Tomohisa Saito (Chugai Pharmaceutical Co. Ltd., Japan)
Population pharmacokinetics and exposure-response assessment of polatuzumab vedotin (Anti-CD79b antibody-drug-conjugate) in patients with relapse/Refractory B-cell lymphoma

Oct 4, 2018 [Thu]

SY13: New Evidence and Technics Which Support Evolution of Systems Modeling in Drug Discovery and Development
Naoki Kiyosawa (Daiichi Sankyo Co. Ltd., Japan)
Patho-physiological network modeling of functionally active biological pathways based on patients’ transcriptome data: an initial step for QSP modeling

Kota Toshimoto (RIKEN, Japan)
Prediction of inter-individual variability of drug pharmacokinetics, effect, and adverse effect by using the virtual clinical study approach

Arthur Goldsipe (MathWorks Inc., USA)
Optimization and validation for complex systems modeling

Mikiko Nakamura (Chugai Pharmaceutical Co. Ltd., Japan)
Safety prediction in human using QSP model combined with PBPK model -Predictability of clinical risk from preclinical studies-
SY14: Xenobiotic Metabolism and Drug Interaction
Hiroshi Yamazaki (Showa Pharmaceutical University, Japan)
Human drug metabolism and disposition in humanized-liver mice and non-human primate models

Wichittra Tassaneeyakul (Khon Kaen University, Thailand)
Roles of drug metabolizing enzymes in drug-induced severe cutaneous adverse reactions

Young-Jin Chun (Chung-Ang University, Korea)
The roles of cytochrome P450 1B1 in cell survival and anti-apoptotic signaling during carcinogenesis

Yune-Fang Ueng (National Research Institute of Chinese Medicine, Taiwan)
7-Ketocholesterol induces the expression of P-glycoprotein and decreases doxorubicin sensitivity in hepatoma and breast cancer cells
SY15: Role of Intestinal Microbiota in Drug Metabolism and Disposition
Takuji Yamada (Tokyo Institute of Technology, Japan)
Human gut microbiota and colorectal cancer

Shingo Ito (Kumamoto University, Japan)
Effect of dysbiosis on drug pharmacokinetics and host physiology in mice

Mikiko Shimizu (Keio University, Japan)
Mechanism of disease prevention and therapeutic effects by probiotics, and drug-probiotics interaction

Jun Kunisawa (National Institutes of Biomedical Innovation, Health and Nutrition, Japan)
Basic and cohort studies for the elucidation of diet- and commensal-mediated control of health and diseases
SY16: Nuclear Xenobioitc Receptors: Metabolism and Diseases
Kouich Yoshinari (University of Shizuoka, Japan)
Hepatocyte proliferation mediated by nuclear receptors CAR and PXR

Hongbing Wang (University of Maryland, USA)
The role of human CAR in the development of hepatocellular carcinoma

Michael Schwarz (University of Tuebingen, Germany)
Regulation of expression of drug-metabolizing enzymes by oncogenic signaling pathways

Wen Xie (University of Pittsburgh, USA)
Xenobiotic receptors in the crossroad of xenobiotic and endobiotic metabolsim
SY17: Mass Spectrometry: Emerging Modality for Drug Development and PD/Tox Marker Discovery
Kosuke Saito (National Institute of Health Sciences, Japan)
Lipid profiling as a tool for understanding mechanisms of drug induced toxicity

Sumio Ohtsuki (Kumamoto University, Japan)
Integrated targeted quantitative proteomic system for drug and biomarker development

Masaru Yoshida (Kobe University, Japan)
Metabolomics for biomarker discovery in the diagnosis of cancers

Kazuyoshi Nozaki (Astellas Pharma Inc., Japan)
The tissue distribution and metabolism of a model prodrug in mice using MALDI imaging mass spectrometry
SY18: Drug-induced Liver Injury
Ruitang Deng (University of Rhode Island, USA)
Transrepression of BSEP through FXR antagonism and Cholestatic Liver Injury

Huiping Zhou (Virginia Commonwealth University, USA)
ER stress and Drug-induced Liver Injury

Kousei Ito (Chiba University, Japan)
Importance of immune response in onset and exacerbation of drug-induced liver injury
SY19: MDO 50 Years Anniversary #2
F. Peter Guengerich (Vanderbilt University, USA)
Cytochrome P450: What we know, recent surprises, & questions for future research

Eric F. Johnson (Scripps Research Institute, USA)
Crystal Structures of Multi-Functional Mammalian P450s: Diversity, Plasticity and Uses

James Halpert (University of Connecticut, USA)
Cytochrome P450 inhibitors: mechanism, selectivity, utility, and role in drug interactions

R. Scott Obach (Pfizer Inc., USA)
How Knowledge of Cytochrome P450 Enzymes is Critical for Drug Research
SY20: From API to Drug Products: Think over the Role of PKPD in Oral Drug Development
Ikumi Tamai (Kanazawa University, Japan)

Kiyohiko Sugano (Ritsumeikan University, Japan)
Oral drug absorption - Physicochemical aspect

Koji Shiraki (Chugai Pharmaceutical Co. Ltd., Japan)
Oral drug absorption -Formulation aspect

Shinji Yamashita (Setsunan University, Japan)
Oral drug absorption – Pharmacokinetic aspect

Gordon L. Amidon (University of Michigan, USA)
Oral drug absorption – Regulatory aspect (BCS and in vivo predictive dissolution)
SY21: Drug Metabolism around the Clock (the Influence of Circadian Rhythm on Drug Metabolism)
Hitoshi Okamura (Kyoto University, Japan)
Molecular mechanism of circadian rhythm and metabolism in mammals

Zheng (Jake) Chen (University of Texas Health Science Center, USA)
Roles of clock-manipulating small molecules in metabolism and aging

Shigehiro Ohdo (Kyushu University, Japan)
The role of molecular clock in the alterations of hepatic metabolism in chronic kidney disease

Oct 5, 2018 [Fri]

SY22: Frontiers of Metabolome Research for Drug Discovery Research
Tomohiro Andou (Axcelead Drug Discovery Partners Inc., Japan)
Translational research and its issues for the promising drug development in pharmaceutical companies

Tomoyoshi Soga (Keio University, Japan)
Multiomics-analysis of colorectal cancer metabolism

Issay Kitabayashi (National Cancer Center Research Institute, Japan)
Molecular mechanism and molecular-targeted therapy for cancer induced by the oncometabolite 2HG

Tappei Takada (University of Tokyo, Japan)
Transporters and pathophysiological metabolome analysis

Emi Kimoto (Pfizer Inc., USA)
Utility of drug transporter proteomics to drive translational ADME: human PK prediction in nonalcoholic steatohepatitis (NASH) patients
SY23: Novel Drug Developmental Tools on DMPK/Toxicity and Their Regulation
Kengo Watanabe (Daiichi Sankyo Co. LTD., Japan)
Applicability of Microphysiological System (MPS) to Drug Discovery and Development

Seiichi Ishida (National Institute of Health Sciences, Japan)
Efforts for the developmet of Pharmacokinetic Tests aimed at Alternatives to Animal Experiments Considering OECD's movements

Yasunari Kanda (National Institute of Health Sciences, Japan)
Development of a safety assessment using human iPS cells

Mizuho Nonaka (Pharmaceuticals and Medical Devices Agency, Japan)
Non-clinical safety assessment of medical products derived from iPS cells
SY24: Crossroad of Endobiotic and Xenobiotic Metabolism in the Liver
Grace L. Guo (Rutgers University, USA)
Crosstalk between bile acid pathway and xenobiotic metabolism

Huichang Bi (Sun Yat-sen University, China)
PXR promotes liver enlargement and liver regeneration in a YAP-dependent manner

Rita Bernhardt (Universität des Saarlandes, Germany)
Adrenal steroid hydroxylases with new functions in drug metabolism